Ligand Pharmaceuticals (LGND) Shares Outstanding (2010 - 2026)

Ligand Pharmaceuticals has reported Shares Outstanding (Entity) for 17 years, with the latest figure at $20.0 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 3.91% year-over-year to $20.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.0 million (up 3.91% YoY) and the FY2025 annual result came in at $19.8 million, up 3.5% from the prior year.
• Shares Outstanding (Entity) improved to $20.0 million in Q1 2026 per LGND's latest filing, from $19.8 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $20.0 million in Q1 2026 and troughed at $16.9 million in Q1 2022.
• A 5-year average of $18.2 million and a median of $17.9 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) rose 1.1% in 2022, then rose 8.83% in 2024.
• Over 5 years, Shares Outstanding (Entity) stood at $17.0 million in 2022, then rose by 3.57% to $17.6 million in 2023, then grew by 8.83% to $19.1 million in 2024, then grew by 3.5% to $19.8 million in 2025, then climbed by 1.29% to $20.0 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $20.0 million, $19.8 million, and $19.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.